The Translational Research Core (TRC) is designed to facilitate high quality translational research at the Moffitt Cancer Center. The TRC provides a means to generate pre-clinical data to support investigator initiated trials and resources to quantify the level/activity of molecular targets from clinical specimens obtained from trials. The functionality provided within the Core provides a vital resource for investigators to design and conduct early phase clinical research of novel agents. The Core's overall goals are to provide efficient and proper collection, handling and processing of biological samples, perform sensitive and specific assays and provide the ability to model the data generated. The TRC continues to increase the number of investigators utilizing their services. The Core has also witnessed a greater number of scientific programs requiring services since the last renewal. The capacity of the pharmacologic section has been expanded by the inclusion of a new UHPLC/Tandem Mass Spectrometry system (Thermo Scientific, Accela/TSQ Quantum). Regarding analyses of pharmacodynamic molecular endpoints, the number of active projects continues to grow and is neariy equally divided between clinical and preclinical projects. The Core requests CCSG Support of $125,995, which is 23% of its operational budget.
The Translational Research Core Facility provides researchers with novel approaches and access to the latest technologies with respect to pharmacokinetic drug quantitation and analysis, measurement of pharmacodynamic endpoints, and high-throughput apoptosis assays and combination index analysis for drug interactions. The core is uniquely positioned to provide researchers with a cost-effective, well-managed facility to accomplish their goals.
|Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986|
|Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149|
|Hampras, Shalaka S; Locke, Frederick L; Chavez, Julio C et al. (2018) Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 59:911-917|
|Bowman-Curci, Meghan; Quinn, Gwendolyn P; Reinecke, Joyce et al. (2018) Comparing fertility preservation resources and policies between NCCN member and non-member institutions. Support Care Cancer :|
|Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997|
|Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843|
|Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590|
|Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950|
|Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75|
|Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585|
Showing the most recent 10 out of 1254 publications